| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S16016 R66486 |
Christensen (Lamotrigine) (All indications), 2024 | Low birth weight (<2500 g) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 0.94 [0.84;1.05] | 395/8,756 141,442/4,467,848 | 141,837 | 8,756 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8978 R30432 |
Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 | Weight at birth <2500 g | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 1.15 [0.99;1.35] C | 172/2,813 91,172/1,707,707 | 91,344 | 2,813 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8974 R30418 |
Hernández-Díaz (Lamotrigine) (Mixed indications), 2014 | Low birth weight (< 2500g) | throughout pregnancy | prospective cohort | unexposed, disease free | Adjustment: No | 1.20 [0.71;2.03] C | 74/1,581 18/457 | 92 | 1,581 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8953 R30312 |
Veiby (Lamotrigine) (Controls unexposed, disease free) b, 2013 | Low birth weight (< 2500 grams) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: Yes |
1.20 [0.50;2.80] excluded (control group) |
6/103 5,024/106,899 | 5,030 | 103 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8954 R30326 |
Veiby (Lamotrigine) (Controls unexposed, sick) b, 2013 | Low birth weight (< 2500 grams) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 1.43 [0.55;3.75] C | 6/103 16/386 | 22 | 103 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 1.05 [0.90;1.23] | 233,295 | 13,253 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Lamotrigine) (All indications; 2: Lamotrigine) (Controls unexposed NOS) (Mixed indications; 3: Lamotrigine) (Mixed indications; 4: Lamotrigine) (Controls unexposed, sick) ;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 8953